

Company Information and Disclosure Statement
Section One: Issuers' Initial Disclosure Obligations

Connectyx Technologies Holdings Group, Inc.
OTCPK: CTYX

Table of Contents

Part A General Company Information 3

Item I The exact name of the issuer and its predecessor (if any) 3

Item II The address of the issuer’s principal executive offices 3

Item III The jurisdiction(s) and date of the issuer’s incorporation or organization 3

Part B Share Structure 3

Item IV The exact title and class of securities outstanding 3

Item V Par or stated value and description of the security 3

Item VI The number of shares or total amount of the securities outstanding for each class of securities authorized 4

Part C Business Information 5

Item VII The name and address of the transfer agent* 5

Item VIII The nature of the issuer’s business 5

Item IX The nature of products or services offered 10

Item X The nature and extent of the issuer’s facilities 13

Part D Management Structure and Financial Information 13

Item XI The name of the chief executive officer, members of the board of directors, as well as control persons 13

Item XII Financial information for the issuer’s most recent fiscal period 16

Item XIII Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence 17

Item XIV Beneficial Owners 17

Item XV The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure 17

Item XVI Management’s Discussion and Analysis or Plan of Operation 18

Part E Issuance History 23

Item XVII List of securities offerings and shares issued for services in the past two years 23

Part F Exhibits 26

Item XVIII Material Contracts 26

Item XIX Articles of Incorporation and Bylaws 27

Item XX Purchases of Equity Securities by the Issuer and Affiliated Purchasers 27

Item XXI Issuer’s Certifications 29

Section One: Issuers' Initial Disclosure Obligations

Part A General Company Information

Item I The exact name of the issuer and its predecessor (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Connectyx Technologies Holdings Group, Inc., a Florida corporation (hereinafter referred to as “we”, “us”, or “our” or “the Issuer”). Name used by predecessor entities in the past five years: (a) Formerly=Storage Innovation Technologies, Inc. until 10-07, (b) Formerly=National Boston Medical, Inc. until 5-04

Item II The address of the issuer's principal executive offices

In answering this item, please also provide (i) the telephone and fax number of the issuer's principal executive offices, (ii) if applicable, the URL of each website maintained by or on behalf of the issuer, and (iii) if applicable, the name, phone number, email address, and mailing address of the person responsible for the issuer's investor relations.

Address: 850 NW Federal Highway Suite 411, Stuart FL 34994
Phone: (800) 526-8006
Fax: (866) 900-1002
Website 1: www.connectyx.com
Website 2: www.medflash.com

Item III The jurisdiction(s) and date of the issuer's incorporation or organization

Provide the issuer's jurisdiction(s) of incorporation or jurisdiction(s) of organization (if the issuer is not a corporation) and the date on which it was incorporated or organized.

The Company was originally incorporated on June 29, 1995, in the State of Nevada; the Company, as of October 25, 2007, and was reincorporated in the State of Florida.

Part B Share Structure

Item IV The exact title and class of securities outstanding.

In answering this item, provide the exact title and class of each class of outstanding securities. In addition, please provide the CUSIP and trading symbol.

CUSIP Number: 20786Q209
Trading Symbol: CTYX
Common Stock Outstanding: 170,052,477
Restricted Common Stock:
Preferred A Stock Outstanding: 34,109,750
Preferred B Stock Outstanding: 256,000

Item V Par or stated value and description of the security

A. Par or Stated Value. Provide the par or stated value for each class of outstanding securities.

We are authorized to issue 1,100,000,000 shares of common stock, par value .0001, and 200,000,000 shares of preferred stock, par value .0001. Preferred stock series A has 200,000,000 shares authorized and 34,109,750 shares outstanding. Preferred Series A is non dilution rights and has 10 votes per share and is convertible to 35% of the company's common stock equity.

Preferred stock series B has 10,000,000 shares authorized and 256,000 shares outstanding. Preferred Series B is convertible to common stock equal to \$0.0075 per share prior to the date of notice of conversion. Each share also includes a warrant with the exercise price of \$.02.

B. Common or Preferred Stock.

1. For common equity, describe any dividend, voting and preemption rights.

N/A

2. For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.

Holdes of Preferred Series A has 10 votes per share and have non dilution rights convertible to 35% of the company's outstanding common stock as filed in restated articles of incorporation. Preferred stock series B has 5,000,000 shares authorized and 256,000 shares outstanding. Preferred Series B is convertible to common stock equal to \$0.0075 per share days immediately prior to the date of notice of conversion. Each share also includes a warrant with the exercise price of \$.02.

3. Describe any other material rights of common or preferred stockholders.

N/A

4. Describe any provision in issuer's charter or by-laws that that would delay, defer or prevent a change in control.

N/A

Item VI The number of shares or total amount of the securities outstanding for each class of securities authorized.

In answering this item, provide the information below for each class of securities authorized. Please provide this information (i) as of the end of the issuer's most recent fiscal quarter and (ii) as of the end of the issuer's last two fiscal years.

Common Stock

	Most Recent Fiscal Quarter	Last Fiscal Year	Previous to Last Fiscal Year
(i) Period end date;	03-31-12	12/31/11	12/31/10
(ii) Number of shares authorized;	1,100,000,000	1,100,000,000	500,000,000
(iii) Number of shares outstanding;	170,052,477*	35,081,537*	215,726,631
(iv) Freely tradable shares (public float);	80,451,998*	25,427,598*	99,420,163

(v) Total number of beneficial shareholders; and	164	141	111
(vi) Total number of shareholders of record.	164	141	111

*Post reverse stock split at a ratio of one (1) share for each fifty (50) shares

Series Preferred Stock

	Most Recent Fiscal Quarter	Last Fiscal Year	Previous to Last Fiscal Year
(i) Period end date;	03-31-2012	12/31/11	12/31/10
(ii) Number of shares authorized;	200,000,000	100,000,000	100,000,000
(iii) Number of shares outstanding; Pref A	34,109,750	34,109,750	34,109,750
(iii) Number of shares outstanding; Pref B	256,000	136,000	0
(iv) Total number of shareholders of record.	13	12	0

Part C Business Information

Item VII The name and address of the transfer agent*

*In answering this item, please also provide the telephone number of the transfer agent, indicate whether or not the transfer agent is registered under the Exchange Act, and state the appropriate regulatory authority of the transfer agent. *To be included in OTCQX or the Current Information OTC Market Tier, the issuer's transfer agent must be registered under the Exchange Act.*

Interwest Transfer Co., Inc.
 Address: 1981 Murray Holladay Road, Suite 100, Salt Lake City, UT 84117
 Phone: (801) 272-9294
 Registered Under Exchange Act: Yes
 Regulatory Authority: Security Exchange Commission (SEC)

Item VIII The nature of the issuer's business

In describing the issuer's business, please provide the following information:

- A. Business Development. Describe the development of the issuer and material events during the last three years so that a potential investor can clearly understand the history and development of the business. If the issuer has not been in business for three years, provide this information for any predecessor company.**

The Company markets a suite of healthcare related intelligent software tools that serves the healthcare industry, including patients, medical providers, and other health care organizations. Our signature product,

Med Flash, enables patients to maintain their personal health and wellness information via the Internet which includes a portable USB flash drive that can be used on any computer with complete privacy, but have available at critical moments. As of December 31, 2010 we no longer offer our revenue cycle software, MRN manager and discontinued technical support on June 30, 2011. All customers are being offered continued services and support through and Manchester DSL, which will offer all MRN customers an alternative and new version of a revenue cycle management software at no charge for the remainder of their current MRN license period.

This business development description must also include:

1. The form of organization of the issuer (e.g., corporation, partnership, limited liability company, etc.);

We are a Florida "C" corporation.

2. the year that the issuer (or any predecessor) was organized;

We were organized and incorporated in the State of Nevada on June 29, 1995. After various name changes and business plans which failed, on October 25, 2007 we changed our name to Connectyx Technologies Holdings Group, Inc. On November 6, 2007, we completed the acquisition of Connectyx Technologies Corp, a Florida corporation, whereby: (a) Connectyx Technologies Corp. became our wholly owned subsidiary; and (b) Connectyx Technologies Corp's shareholders, then owning all of its outstanding shares, received one (1) share of our common stock for each one (1) share of Connectyx Technologies Corp.'s common stock held, which resulted in our issuing an aggregate of 2,215,869 shares of our common stock to the Connectyx Technologies Corp. shareholders. Our acquisition of Connectyx Technologies Corp was approved by the Connectyx Technologies Corp's and our Board of Directors, as well as by a majority vote of our and Connectyx Technologies Corp.'s shareholders. The Articles of Share Exchange and Plan of Exchange for this transaction were filed with the Florida Department of State, Division of Corporations, on or about November 8, 2007. On October 30, 2007 we changed our jurisdiction of incorporation from Nevada to Florida and we adopted amended articles of incorporation that authorize us to issue 500,000,000 shares of common stock and 100,000,000 shares of preferred stock. On April 8, 2010 by majority vote the Shareholders approved approve an amendment to our Second Amended and Restated Articles of Incorporation (the "Charter") to increase the number of our authorized shares of capital stock from a total of 600,000,000 shares, consisting of 500,000,000 shares of \$.0001 par value Common Stock (the "Common Stock") and 100,000,000 shares of \$.0001 par value Preferred Stock (the "Preferred Stock"), to a total of 1,300,000,000 shares, consisting of 1,100,000,000 shares of Common Stock and 200,000,000 shares of Preferred Stock in the form of a First Articles of Amendment to the Charter (the "Charter Amendment").

3. the issuer's fiscal year end date;

Our fiscal year ends on December 31.

4. whether the issuer (or any predecessor) has been in bankruptcy, receivership or any similar proceeding;

We were previously in Chapter 7 bankruptcy under a prior name, National Boston Medical Inc. On or about November 5, 2007, the Bankruptcy Court approved the trustee's final report and accounts In National Boston Medical, Inc (Case No. 00-4517-JBR) (US Bankruptcy Court, Dist. Mass. Western Division). Apart from this bankruptcy matter, we have never been involved in a bankruptcy, receivership or any similar proceeding.

5. any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets;

As noted above in Item 2, on November 6, 2007, we (then and still known as Connectyx Technologies Holdings Group, Inc.) completed the acquisition of Connectyx Technologies Corp whereby: (a) Connectyx Technologies Corp. became our wholly owned subsidiary; and (b) Connectyx

Technologies Corp's shareholders, then owning all of its outstanding shares, received one (1) share of our common stock for each one (1) share of Connectyx Technologies Corp.'s common stock held, which resulted in our issuing an aggregate of 2,215,869 shares of our common stock to the Connectyx Technologies Corp. shareholders. Our acquisition of Connectyx Technologies Corp was approved by the Connectyx Technologies Corp's and our Board of Directors, as well as by a majority vote of our and Connectyx Technologies Corp.'s shareholders. The Articles of Share Exchange and Plan of Exchange for this transaction were filed with the Florida Department of State, Division of Corporations, on or about November 8, 2007.

Apart from our acquiring Connectyx Technologies Corp, we have not made a material reclassification, acquisition, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;

All Leases, Note and Loans in arrears have workout payment plans that are being resolved and the debts are being paid and reduced on schedule.

7. any change of control;

Yes. After April 18, 2007, when Ronn Schuman became our sole director, we issued 30,000 post reverse stock split common shares to Ronn Schuman for services rendered as our Director on October 15, 2007. On November 7, 2007, we issued an aggregate of 2,215,869 shares of our common stock to Connectyx Technologies Corp.'s shareholders in connection with our acquiring Connectyx Technologies Corp. whereby: (a) Connectyx Technologies Corp became our wholly owned subsidiary; and (b) Connectyx Technologies Corp.'s shareholders, owning all of its outstanding shares, received one (1) share of our common stock for each one (1) share of Connectyx Technologies Corp.'s common stock held, which resulted in our issuing an aggregate of 2,215,869 shares of our common stock to Connectyx Technologies Corp.'s shareholders.

8. any increase of 10% or more of the same class of outstanding equity securities;

Yes. As noted in Item 7, on October 15, 2007, we issued 30,000 common shares to Ronn Schuman for services rendered. On November 7, 2007, we issued an aggregate of 2,215,869 common shares to Connectyx Technologies Corp.'s shareholders in connection with our acquiring that corporation. On November 5, 2007 we approved a forward stock split at a ratio of ten shares for each one share held for all shareholders of record as of November 19, 2007 with an effective date of November 28, 2007.

9. any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization;

Apart from the acquisition of Connectyx Technologies Corp described in Items A2 and A5 above, on or about March 1, 2007, our former sole Director approved a one thousand (1,000) share for one (1) share reverse stock split, which became effective on October 29, 2007.

On November 5, 2007 we approved a forward stock split at a ratio of ten (10) shares for each one (1) share held for all shareholders of record as of November 19, 2007 with an effective date of November 28, 2007.

We approved a reverse stock split at a ratio of one (1) share for each fifty (50) shares held for all shareholders as of a record date of July 16, 2010 with an effective date of August 23, 2010.

We have not engaged and do not anticipate in engaging in any other stock split, or stock dividend, recapitalization, acquisition, acquisition, spin-off, or reorganization

On October 30, 2009 and December 4, 2009 Connectyx Technologies Holdings Group, Inc. restated its articles of incorporation as approved by the Board of Directors and shareholders as written as part of its annual meeting – proxy statement on September 30, 2009 and on resolution on December 3, 2009. The resulting resolutions created two new classifications of Preferred Stock; A and B of which the Company issued 100,000,000 shares; 34,109,750 – Preferred Stock A and 5,000,000 allocated to Preferred Stock B. As part of this reclassification of shares the Company did reduce its Common stock by 34,107,750 as part of the Preferred Stock A transaction.

On March 15, 2010 the Board of Directors called for a special meeting of the shareholders for the approval of a charter amendment to the Company's Second Amended and Restated Article of Incorporation to increase the number of authorized shares of capital stock from a total of 600,000,000 shares, consisting of 500,000,000 shares of \$0.0001 par value Common Stock, and 100,000,000 shares of \$0.001 par value Preferred Stock, to a total of 1,300,000,000 shares consisting of 1,100,000,000 shares of Common stock and 200,000,000 shares of Preferred Stock in the form of a First Articles of Amendment to the Company's Charter. The special meeting was held April 8, 2010 at 9am located at the offices of Greenberg and Traurig, P.A in Boca Raton, FL and the amendments were approved and subsequently filed with the state of Florida on 4-19-10.

On July 18, 2011 the Board of Directors called for a special meeting of the shareholders for the approval of a charter amendment to the Company's Second Amended and Restated Article of Incorporation to increase the number of authorized shares of Preferred B stock from a total of 5,000,000 Preferred stock series B to 10,000,000 shares. Preferred stock series B has 10,000,000 shares authorized and 234,000 shares outstanding. Preferred Series B is convertible to common stock equal to \$0.0075 per share days immediately prior to the date of notice of conversion. Each share also includes a warrant with the exercise price of \$.02. The special meeting was held July 18, 2011 at 1pm located at the offices of Connectyx at 850 NW Federal Highway, Suite 411 Stuart, FL 34994 and the amendments were approved and subsequently filed with the state of Florida on 7-19-2011.

10. any delisting of the issuer's securities by any securities exchange or deletion from the OTC Bulletin Board; and

No.

11. any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations and any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.

The Company is vigorously defending a frivolous claim filed by Big Apple Equities, LLC to convert approximately \$135,000 of purported debt obligation into free trading unregistered shares of our common stock. We intend to vigorously defend against the claim filed by Big Apple using all defenses available to us.

B. Business of Issuer. Describe the issuer's business so a potential investor can clearly understand it. To the extent material to an understanding of the issuer, please also include the following:

1. the issuer's primary and secondary SIC Codes;

Primary Code: 5045 – Wholesale – Computers and Peripheral Equipment and Software
Secondary Code: 7370 – Computer Services

2. if the issuer has never conducted operations, is in the development stage, or is currently conducting operations;

We are currently conducting operations and have done so since November 7, 2007. When we acquired our wholly owned subsidiary, Connectyx Technologies Corp., we adopted Connectyx Technologies Corp's business, which it had conducted since March 2003.

3. whether the issuer is or has at any time been a "shell company"

The Company has never been classified as a shell in its prior filings. While new management has not been involved in the day to day operations of the Company since inception, it accepts the accuracy of the Company's prior filings and further states categorically that the Company has never been a shell since the date of the change in control.

4. the names of any parent, subsidiary, or affiliate of the issuer, and its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure statement;

We have one wholly owned subsidiary, Connectyx Technologies Corp., through which we conduct our operations, as noted in our financial statements.

5. the effect of existing or probable governmental regulations on the business;

Although our MedFlash product is 100% owned and controlled by the consumer upon their purchase of it and we do not retrieve information or access it after sale, because our MedFlash product contains personal health and lifestyle related information, though we are not subject to the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), the Company has instituted all the necessary encrypted – secure safeguards to protect its members information.

6. an estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

We have not spent any funds on research and development since our inception; however, prior to our acquisition of Connectyx Technologies Corp. as our wholly owned subsidiary, that corporation spent approximately \$10,000 in 2005 and \$10,000 in 2006 on research and development.

7. costs and effects of compliance with environmental laws (federal, state and local); and

Our business and products are not subject to environmental laws; as such, we have not spent any funds on environmental laws compliance. Further, we do not anticipate any future costs of compliance with environmental laws and do not expect that our operations will be subject to environmental laws.

8. the number of total employees and number of full-time employees.

We currently have a total of 5 employees, directors and consultants, as follows: (a) Ronn Schuman, Chief Executive Officer/Director; (b) Tracy Sloan, CPA, Interim Controller, (c) Dr. Gary Kabinoff, Medical Advisor, (d) Jon Pevzner, Administrator, (f) William Carlson, Chief Medical Officer - Director


Item IX The nature of products or services offered

In responding to this item, please describe the following so that a potential investor can clearly understand the products and services of the issuer:

A. principal products or services, and their markets;

MedFlash

It seems trite to say that people are individually responsible for their own personal health. After all, what could be more obvious? We individually suffer the consequences of bad health and reap the rewards of good health. Meanwhile, health care providers are only responsible for providing us with expert medical attention related primarily to our illnesses, conditions or injuries, which is not the whole story of our health.



11/4/2009



This separation of health and medicine is reflected in record-keeping as well. We keep track of our health, noting our weight, our physical stamina, our sleep quality, and so on. If we have a chronic disease – such as diabetes, high-blood pressure or high cholesterol to name a few – we also monitor things like blood sugar, blood pressure and blood lipid levels because these levels will determine our overall health. Meanwhile, our various health care providers document their encounters with us by creating and keeping medical records known as EMR’s or PHR’s (Electronic Medical or Health Records). In addition to things we track for ourselves, we may also track parts of these medical records as part of our personal health monitoring.

For years we have been told we need to manage our own personal health records (PHR’s) and health care providers have been encouraged to mobilize their paper-based medial records by creating Electronic Medical Records (EMR’s). The term Electronic Health Record has emerged to reflect the fact that doctors need patient provided information to complete their EMR’s. And, the concept of a unified patient record has emerged because one patient’s medical records are spread across numerous health care providers. Tremendous increases in the efficiency of the delivery of healthcare, improved outcomes and prescription drug compliance are being realized through the unification of medical records.

A new movement in America known as “wellness” has developed to address the need for overall healthcare and not just good medical care. Meanwhile, a whole world of general health information has sprouted on the Internet. As a result, we are not only encouraged to collect our personal health records; we are enabled to collect general information that is related to our personal health. Quickly, we realize that information is only part of the challenge of managing our personal health. We have to acquire, marshal and then act on the information that is available to us.

Similarly, it turns out, that our electronic personal health manager (ePHM) is only one part of our personal health management. We need to learn, we need to choose and we need to take action. A personal health manager can help us do this, but only if it does much more than simply keep records. To take just one example, suppose we want to manage our blood pressure proactively in addition to taking medications. We need a diet, and that takes a calorie counter. We need to monitor our progress and that takes a bathroom scale. We want to portion our food and that takes a kitchen scale and other measuring devices. We want support in our diet and that takes a social network. We need a cohesive plan and that takes more than a diet; we need a blood pressure management program. And then there is exercise and that takes equipment, monitors, and another social network perhaps. This is what personal health management looks like; it’s a lot more than a personal health record.

Major developments are making this proactive health management more and more possible. One of those developments is the MedFlash PHM, a set of Personal Health Management Tools. Combining personal health record tools with disease management tools, health activity tools, social networking tools and health information tools provides people with a platform for managing their health. Other related developments include the movement to Electronic Medical Records, the expansion of insurance coverage for disease management programs, and the move to unify patient records by Microsoft, Kaiser Permanente and the National Health Information Network. Meanwhile, online information continues to proliferate. And, books now target specific personal health needs with complete programs for proactive health management.

All these developments increase the need for a personal health manager to enable individuals to marshal information, manage their activities, connect with people and monitor their progress. MedFlash PHM tools fit into the landscape by actualizing available health information in ways individualized and customized to personal needs. One size does not fit all. One individual is a high-performance athlete, another is an aging diabetic and someone else is a recovering alcoholic. Each has a different challenge and needs to take different steps. The platform to support these disparate personal health challenges is one that lets the individual choose the content and the activities while the platform provides the means.

A Personal Health Manager must provide secure connectivity from the personal computer into the Internet cloud and across many health care providers. In addition it must provide easy access and affordable use. And, it must connect people to people, not just information to information. MedFlash’s approach is a platform approach that allows individuals to structure their use according to their personal conditions, needs and goals. It is not a platform that presumes to know what members ought to do. Rather, it focuses on connecting members to resources and services that empower them to do exactly what they are personally motivated to do. After all; one size does not fit all.

B. distribution methods of the products or services;

MedFlash is sold directly to consumers nationwide through our internal sales team and through our distribution partners who then market and sell MedFlash directly to consumers. Our future plans include MedFlash being marketed to a variety of other business channels, including insurance companies, universities, large employers, and national associations.

C. status of any publicly announced new product or service;

Connectyx announced its intent to build and market a Pet health and benefits web product portal similar to its MedFlash product offering, geared toward consumer pet owners.

D. competitive business conditions, the issuer's competitive position in the industry, and methods of competition;

Due to the fact that the Emergency Medical Records (EMR) and Personal Health Records (PHR) markets are still unfolding, traditional competitive models may not be relevant. Management believes, but still can not guarantee the success of MedFlash for the reason that the market is still in its infancy and there are many unknown factors that could affect the overall success of the MedFlash product(s). Furthermore, the company may be unable to effectively compete because existing or potential competitors may have superior financial, technical, distribution, marketing, sales and other resources, as well as significantly greater name recognition and established positions in the markets we serve.

It is important to note that increased competition could force us to lower our prices or offer services at a higher cost to us, which could reduce our operating income. Management believes that to complete in this market place, the company's future plans over the next 5 years, include attempting to increase their market share by: (a) offering new technologies/products that will potentially give them a competitive advantage over our competitors, including a next generation MedFlash product that will be a open social network that will allow its members, first responders, emergency room or healthcare professionals to view information contained in the MedFlash portal without a personal computer, via mobile device(s); (b) launch a major marketing campaign targeting prospective customers to introduce and develop interest in our product offerings; (c) attempt to secure an MedFlash distribution or private label contract with a membership groups, employer, or insurance company of substantial size to materially increase our revenues; (d) increase our marketing of MedFlash by selling to new business channels, including , universities, large employers, and national associations; (e) hire approximately 20 customer - sales representatives over the next five years to market our products; (f) compile a database of physicians and surgeons that our sales representatives may contact as potential customers; and (g) merge or acquire another company that will increase our market share.

E. sources and availability of raw materials and the names of principal suppliers;

NA

F. dependence on one or a few major customers;

We are not dependent upon one or a few customers and we do not expect to become so in the future.

G. patents, trademarks, licenses, franchises, concessions,

Our subsidiary, Connectyx Technologies Corp was granted U.S. Trademark #3,739,453 for the protection of the MedFlash name, graphics and proprietary USB operating software. This protection includes International Cl.: 9 designations in class 9 (U.S. LS. 21, 23, 26, 36 and 38). A registered trademark grants a bundle of exclusive rights upon the registered owner, including the right to exclusive use of the mark in relation to the products or services for which it is registered.



Our subsidiary, Connectyx Technologies Corp. applied for trademark protection with the United States Patent and Trademark Office under serial number 78467127 for the following on August 13, 2004 which trademark registration was approved on November 7, 2006 under registration number 3169574:



Our subsidiary, Connectyx Technologies Corp. applied for trademark protection with the United States Patent and Trademark Office under serial number 78493994 for the following on October 4, 2004 which trademark registration was approved on December 20, 2005 under registration number 3033276:



H. The need for any government approval of principal products or services and the status of any requested government approvals.

None

Item X The nature and extent of the issuer's facilities.

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

We lease a cooperative office space at Crexent Business Center located at 850 NW Federal Highway Suite 411, Stuart, FL 34994. – Lease is six month at a rate of \$95 per month.

Part D Management Structure and Financial Information

Item XI The name of the chief executive officer, members of the board of directors, as well as control persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Officers and Directors. In responding to this item, please provide the following information for each of the issuer's executive officers, directors, general partners and control persons, as of the date of this information statement:

1. Full name;
2. Business address;
3. Employment history (which must list all previous employers for the past 5 years, positions held, responsibilities and employment dates);

**4. Board memberships and other affiliations;
5. Compensation by the issuer; and
6. Number and class**

Ronn Schuman, Chief Executive Officer and Director

Business address: 850 NW Federal Highway Stuart, FL 34994

Employment history / Board Memberships & other affiliations: Mr. Schuman, CEO for CTC, has an extensive background in healthcare business administration and executive strategic planning. He has served as Vice President of Business Development/Operations for Liberty Medical from 1997 to 1999, a \$100M medical supply company, (PLMD) and was their Compliance Officer for two years. Mr. Schuman has owned and operated numerous medical equipment companies over the last 25+years. He is a registered and licensed respiratory clinician, A Medicare – CMS consultant and has a bachelor's degree in business from the University of Phoenix, AZ.

In 1987 Mr. Schuman created ACT, Accessible Care Together and ACT Software, which were the beginning models for one call seamless healthcare networks. The companies had over 50 subscribers throughout the NY - TRI State area. Some of Mr. Schuman's other areas of expertise are, team facilitation, medical billing, call center development, mail order fulfillment and management - process consulting. Mr. Schuman is also an accreditation healthcare surveyor for the Accreditation Commission for HealthCare, ACHC.

Compensation by the issuer: Salary is \$125,000 annually (**Partially Deferred**).

William E. Carlson, MD, Chief Medical Officer and Director

Business address: 850 NW Federal Highway Stuart, FL 34994

Employment history / Board Memberships & other affiliations: Dr. Carlson is a Board Certified Orthopaedic Surgeon who has been in practice of his specialty since 1986. Originally from the Chicago area, Dr. Carlson attended the University of Illinois where he received a Bachelor of Science in Biology, followed by his Medical Degree from St. Louis University School of Medicine, in St. Louis, Missouri. Dr. Carlson completed Orthopaedic Residency at Wayne State University in Detroit, Michigan. He began his career in the Minneapolis area, initially at Comprehensive Medical Care, a multi-specialty group with more than sixty-five physicians, becoming Partner and Board member prior to a corporate acquisition. Subsequently, Dr. Carlson established his first orthopaedic specialty practice serving the northwest region of Minneapolis.

After relocating to Florida, Dr. Carlson co-founded South Florida Orthopaedics & Sports Medicine, and has been its Manager Partner since inception. As a member of the Medical Staff at Martin Memorial Health Systems, he has served on the Medical Executive Committee for the past 10-1/2 years. He is the former President of the Medical Staff of Martin Memorial Health Systems, and was a member of the Board of Directors of Martin Memorial Health Systems. He serves on the Board for several corporate, educational and non-profit entities.

Compensation by the issuer: Salary is \$50,000 annually as Director and Chief Medical Officer (**Currently Deferred**)

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Disclosure of Family Relationships. Describe any family relationships among and between the issuer's directors, officers, persons nominated or chosen by the issuer to become directors or officers, or beneficial owners of more than five percent (5%) of the any class of the issuer's equity securities.

None

D. Disclosure of Related Party Transactions. Describe any transaction during the issuer's last two full fiscal years and the current fiscal year or any currently proposed transaction, involving the issuer, in which (i) the amount involved exceeds the lesser of \$120,000 or one percent of the average of the issuer's total assets at year-end for its last three fiscal years and (ii) any related person had or will have a direct or indirect material interest. Disclose the following information regarding the transaction:

1. The name of the related person and the basis on which the person is related to the issuer;
2. The related person's interest in the transaction;
3. The approximate dollar value involved in the transaction (in the case of indebtedness, disclose the largest aggregate amount of principal outstanding during the time period for which disclosure is required, the amount thereof outstanding as of the latest practicable date, the amount of principal and interest paid during the time period for which disclosure is required, and the rate or amount of interest payable on the indebtedness);

4. The approximate dollar value of the related person's interest in the transaction;
and
5. Any other information regarding the transaction or the related person in the context of the transaction that is material to investors in light of the circumstances of the particular transaction.

None

E. Disclosure of Conflicts of Interest. Describe any conflicts of interest. Describe the circumstances, parties involved and mitigating factors for any executive officer or director with competing professional or personal interests.

None

Item XII Financial information for the issuer's most recent fiscal period

Instruction to Item XII: The issuer shall post the financial statements required by this Item XII through the OTC Disclosure and News Service under the appropriate report name for the applicable period end. (If the financial statements relate to a fiscal year end, publish it as an "Annual Report," or if the financial statements relate to a quarter end, publish it as a "Quarterly Report" or "Interim Report") The issuer must state in its disclosure statement that such financial statements are incorporated by reference. The issuer must also (i) provide a list in the disclosure statement describing the financial statements that are incorporated by reference, (ii) clearly explain where the incorporated documents can be found, and (iii) provide a clear cross-reference to the specific location where the information requested by this Item can be found in the incorporated documents.

The issuer shall provide the following financial statements for the most recent fiscal period (whether fiscal quarter or fiscal year).

1. balance sheet;
2. statement of income;
3. statement of cash flows;
4. statement of changes in stockholders' equity;
5. financial notes; and
6. audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with generally accepted accounting principles (GAAP) by persons with sufficient financial skills.

Information contained in annual financial statements will not be considered current more than 90 days after the end of the issuer's fiscal year immediately following the fiscal year for which such statement are provided, or with respect to quarterly financial statements, more than 45 days after the end of the quarter immediately following the quarter for which such statements are provided.

The following Financial Statements have been posted to Pink Sheets for the Quarter ending March 31, 2012.

1. balance sheet;
2. statement of income;
3. statement of cash flows;
4. statement of changes in stockholders' equity; and
5. financial notes;

Item XIII Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence

Please provide the financial statements described in Item XII above for the issuer's two preceding fiscal years. Instruction to Item XIII: The issuer shall either (i) attach the financial statements required by this Item XIII to its initial disclosure statement or (ii) post such financial statements through the OTC Disclosure and News Service as a separate report under the name of "Annual Report" for the applicable fiscal year end. The issuer must state in its disclosure statement that such financial statements are incorporated by reference. The issuer must also (x) provide a list in the disclosure statement describing the financial statements that are incorporated by reference, (y) clearly explain where the incorporated documents can be found, and (z) provide a clear cross-reference to the specific location where the information requested by this Item can be found in the incorporated documents.

The following Financial Statements have been posted to Pink Sheets for the Fiscal Years ending March 31, 2012, 2010, 2009, and December 31, 2008.

1. balance sheet;
2. statement of income;
3. statement of cash flows;
4. statement of shareholder equity
5. notes to the financial statements

Item XIV Beneficial Owners

Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%) of any class of the issuer's equity securities. To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Name & Address	Number of Beneficially Shares Owned	Percentage Beneficially Owned
Ronn Schuman CEO & Director 850 NW Federal Hwy Suite 411, Stuart, FL 34994	Pref Series A 15,715,000 Common Stock 362,600	46.07% <1%
Jose Bardelas, MD 850 NW Federal Hwy Suite 411, Stuart, FL 34994	Common Stock 26,500,000	9.5%

Item XV The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure

1. Investment Banker

None

2. Promoters

None

3. Counsel

Name: Jeffery Klein, Esq
Address: 301 Yamato Road # Suite 1240
Boca Raton, FL 33431
Phone: (561) 953-1126

4. Accountant or Auditor - the information shall clearly (i) describe if an outside accountant provides audit or review services, (ii) state the work done by the outside accountant and (iii) describe the responsibilities of the accountant and the responsibilities of management (i.e. who audits, prepares or reviews the issuer's financial statements, etc.). The information shall include the accountant's phone number and email address and a description of the accountant's licensing and qualifications to perform such duties on behalf of the issuer.

None

5. Public Relations Consultant(s)

6. Investor Relations Consultant

7. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement - the information shall include the telephone number and email address of each advisor.

None

Item XVI Management's Discussion and Analysis or Plan of Operation

Instructions to Item XVI

Issuers that have not had revenues from operations in each of the last two fiscal years, or the last fiscal year and any interim period in the current fiscal year for which financial statements are furnished in the disclosure statement, shall provide the information in paragraphs A and C of this item. All other issuers shall provide the information in paragraphs B and C of this item.

The discussion and analysis shall focus specifically on material events and uncertainties known to management that would cause reported financial information not to be necessarily indicative of future operating results or of future financial condition.

Issuers are not required to supply forward-looking information. This is distinguished from presently known data that will impact upon future operating results, such as known future increases in costs of labor or materials. This latter data may be required to be disclosed.

B. Management's Discussion and Analysis of Financial Condition and Results of Operations.

1. Full fiscal years. Discuss the issuer's financial condition, changes in financial condition and results of operations for each of the last two fiscal years. This discussion should address the past and future financial condition and results of operation of the issuer, with particular emphasis on the prospects for the future. The discussion should also address those key variable and other qualitative and quantitative factors that are necessary to an understanding and evaluation of the issuer. If material, the issuer should disclose the following:

FORWARD LOOKING STATEMENTS

Certain portions of this report, and particularly the Management's Discussion and Analysis of Financial Condition and Results of Operations, and the Notes to Consolidated Financial Statements, contain forward-looking statements which represent the Company's expectations or beliefs concerning future events. The Company cautions that these statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements

Nature of Business

Connectyx Technologies Holdings Group, Inc. provides products in the health care market which includes business intelligent software, which provides its Personal Health and Wellness Manager, MedFlash. The MedFlash product is an easy to use Personal Health and Lifestyle Record & Portal that is flash drive enabled. MedFlash contains an emergency flash drive with a web portal that can contain the owner's complete medical and key information. Stored MedFlash information can be accessed on any computer securely with complete privacy for the members.

The MedFlash ePHM

The MedFlash proprietary electronic personal health manager is anchored by an online portal which provides a simple user interface, optimized so that members can easily enter, store and manage their critical health information.

One key to the MedFlash electronic personal health manager is the proprietary MedFlash USB drive, which incorporates flash memory technology and connects to personal computers via the Internet, mobile phone and a standard USB interface. With a distinctive red exterior casing emblazoned with the MedFlash Logo- symbol, the MedFlash drive is also highly visible and extremely portable.

The MedFlash proprietary synchronization software makes it easy for members to synchronize selected information from the online electronic personal health manager portal to their portable MedFlash drive. MedFlash provides a proprietary "line item lock" that enables users to control which information flows from their online PHR to their portable MedFlash USB drive. MedFlash synchronization software will in the future also enable members to integrate their smart devices and computer peripherals, such as document scanners, blood pressure cuffs and fax modems.

In addition to the Internet Portal, Mobile App, USB, the comprehensive MedFlash electronic personal health manager includes a 24/7 call center and personal I.C.E. (In Case of Emergency) portal,. The latter enables access to a member's emergency medical profile and health information via toll-free call center, an online emergency portal or the MedFlash portable USB drive. The MedFlash drive can also include personal documents uploaded by members such as x-ray images, doctors' notes, living wills or photographs.

There are also lifestyle and wellness features that can provide significant cost and liability savings for employers and insurers.

The current MedFlash application that installs from the Internet and a USB drive to the member's computer is also being developed in a future release to an open synchronization tool which will be part of the MedFlash Personal Health Network.

This will accomplish two usability goals;

1. Decouples synchronization from the web portal, allowing new users to begin their PHR online and then add their devices later, thereby accommodating free trials, affiliate programs and a new sales channel that begins and ends online.
2. Expands to connect with other online PHRs and multiple devices and services, such as blood glucose meters, prescription interaction services, smart phones, calorie counters, prescription reminder services, etc.

The MedFlash system is safe and secure, protected behind an encrypted system located in a hardened facility offering Tier One through Tier Three protection.

Connectyx also has established a relationship with a Rackspace to administer the electronic personal health manager system as the volume of MedFlash members grows. Rackspace servers have demonstrated that they can easily manage tens of millions of potential MedFlash members.

The common theme behind every advance it makes to the MedFlash system is Connectyx's desire to provide consumers with a cost effective product that is meaningful and helps them to improve the quality of life and potentially can help save lives.

Approach to the Market

Those values and that desire to provide consumers with a truly impactful personal health manager can be seen in nearly every aspect of Connectyx, including its approach to market. The company recognized early on that positioning the PHR as a standalone product simply would not provide consumers with the kind of in depth interactive features they need to become more engaged in their healthcare. That is why, although MedFlash incorporates the traditional PHR, it goes well beyond that static technology. In fact, the MedFlash approach is one designed to appeal to all three viewpoints in the market today: electronic personal health record, electronic personal health manager and personal health network (PHN).

Connectyx also believes that in the future it may communicate and or have partnerships with EMR's (Electronic Medical Record Providers and Microsoft HealthVault to expand its reach and scope of use.

Privacy has also been a significant consideration in the development of MedFlash. For example, members have the option to block individuals from seeing specific information on the USB flash drive or web portal. Too, many believe that security concerns will most likely dissolve once members become acquainted with their personal health record. In fact, the CHCF reports that privacy concerns declined by nearly 50 percent once respondents actually began using a personal health record.

A Multi-faceted Approach

Primarily a consumer product, MedFlash is currently available at the pharmacy counters of HEB, other retailers and benefit groups - membership organizations throughout the U.S.

While retail pharmacies constitute a large segment of their target market, Connectyx isn't limiting its scope to consumers. The company has also identified organizations that could benefit from MedFlash and have taken a proactive approach to marketing it as such.

To ensure success in the association market, Connectyx is also addressing the unique challenges membership organizations face with renewals through exclusive branding opportunities designed to increase the organization's exposure. By branding the MedFlash USB with the organization logo, consumers are continually reminded of the organization and are more likely to renew their membership.

It is also useful as a promotional item for healthcare and pharmaceutical companies. These organizations can take branding one step further by including health and wellness information related to their product or drug within the flash drive, such as reminders and tips on how to keep cholesterol low.

Connectyx also sees value in pursuing opportunities within the provider market. Recent stimulus funding and mandates within healthcare reform have brought personal health records front and center among physicians, hospitals and health systems that are seeking stimulus funding for the adoption of certified Electronic health records under the American Recovery and Reinvestment Act (ARRA). In fact, they are required to provide patients with PHRs by 2013 in order to meet the ARRA criteria for meaningful use, as they are currently proposed.

This personal health record requirement will not only improve care outcomes and quality, but also cut costs for providers and patients as health and wellness improve – a mission that Connectyx also hopes to achieve with the widespread consumer adoption of the MedFlash electronic personal health manager.

2. Interim Periods. Provide a comparable discussion that will enable the reader to assess material changes in financial condition and results of operations since the end of the last fiscal year and for the comparable interim period in the preceding year.

- Announced that the company has been approved by the Veterans Administration to utilize the VA's enhanced Blue Button ® initiative for downloading personal medical records.
- Announced today the addition of vision care health plans from Vision Care Direct (VCD) for MedFlash subscribers.
- Signed a marketing agreement with Provider Services of America, (PSA). PSA maintains relationships with many physician networks and provides PSA with access to more than 400,000 physicians and urgent care centers as well as hospitals and other health-related business entities.
- Entered into a marketing agreement with AMAC.US, a competitor of AARP with over 150,000 members. AMAC will be including MedFlash as part of its membership program.
- MedFlash® became a preferred vendor of the National EYEPA's twenty-seven state Independent Professional Associations (IPA) representing approximately 4,500 doctors -- 4,200 OD's (Doctors of Optometry) and 300 MD's and a total of 6,600 physician locations.

These groups have the potential to give us access to millions of consumer members and we are testing a variety of new marketing programs to accelerate the customer acquisition process. It is important to note that Connectyx has continued to have new members sign up weekly and is generating revenue on a consistent basis with members from all fifty states. It is management's goal to continue to reduce its operating burn rate and to increase sales in order to achieve a positive cash flow position, which will lead to a profitable operating and sustainable business model. Early indications from our recent success in building our distributor network are very positive and we anticipate substantial revenue recognition in our current quarter.

Significantly, we currently are in negotiations with a number of large member organizations with the demographics that are the highest reported users of personal medical records that are offered by MedFlash. We anticipate these negotiations to result in at least one alliance/contract that will be very accretive to our revenues and profits.

Some of the newest features and benefits that have been, or are, in the process of being added to our health and wellness platform are:

- RN Telemedicine – Connectyx now offers thir MedFlash member the ability to speak with a RN 24/7 as part of their annual \$19.95 membership with additional access to an audio reference medical library.
- MedFlash is adding a variety of new benefits that will allow for discounted drugs, wellness programs and other tools that will continue to empower its membership to become more engaged in managing key elements of their health profile.

It is also important to note that 2012 is the year when the health care community will be required to provide Personal Health Records to patients as part of its compliance with the "Meaningful Use," requirements of the Health Information Technology for Economic and Clinical Health Act (HITECH Act). New studies are clearly indicating more individuals are signing up for personal health and wellness programs as this market continues to grow-- a market in which Connectyx is developing into one of the leading companies in capturing early market share position.

As stated earlier, new members continue to sign up every week as our marketing efforts gain traction. We constantly are improving MedFlash to attract more subscribers, physician networks and member organizations. Since the beginning of 2011, we have improved MedFlash with the following new enhancements:

- MedFlash® members can now access their MedFlash ICE profile using quick response (QR) scan codes which are printed on their emergency identification cards.
- MedFlash® members can now utilize the MedFlash Portal through their Mac computers A Mobile application for Smart phones
- In June, we launched a major advertisement with our strategic partner, MASA in USA Today's new national travel guide that was published and distributed in all fifty states with 100,000's of copies that are now available on newsstands. Targeted to people planning vacations, the MedFlash/MASA half page advertisement will highlight the benefits of travelers having access to their personal medical records in the event of an accident or other emergency. Ready to brief any doctor, ER physician or other medical professional in an instant, MedFlash provides paramedics and emergency room staffs with access to the information they need to properly provide care when a patient is incapacitated or unresponsive. This national advertising initiative is designed to support the internal marketing of MedFlash to recently signed member organizations.
- Is continuing with the planning and development of its third phase of product development-- MedFlash III, Patient - Doctor Health and Wellness Social Network Portal, which supports the doctor-patient relationship by providing a communication loop that allows the doctor's office to asynchronously communicate with their patients, both individually and collectively.

Some of the new enhancements that will be added to our online MedFlash portal in the future are but not limited too:

- A medication analysis tool which will be an added benefit of maintaining drug safety records. With the increasing occurrence of many individuals being prescribed medications from multiple physicians and prescriptions being filled at more than one pharmacy, the importance of maintaining accurate drug records is critical and, in some instances, life saving. As an added benefit, MedFlash subscribers will have free access to this utility that will review all of their medications for possible side effects and contraindications as a result of taking multiple medications and the side effects of mixing them together producing, in some cases, a life threatening synergistic effects.

C. Off-Balance Sheet Arrangements.

1. In a separately-captioned section, discuss the issuer's off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the issuer's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. The disclosure shall include the items specified in paragraphs C(1)(i), (ii), (iii) and (iv) of this Item XVI to the extent necessary to an understanding of such arrangements and effect and shall also include such other information that the issuer believes is necessary for such an understanding.

None

2. As used in paragraph C of this Item XVI, the term off-balance sheet arrangement means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the issuer is a party, under which the issuer has:

- i. Any obligation under a guarantee contract that has any of the characteristics identified in paragraph 3 of FASB Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others (November 2002) ("FIN 45"), as may be modified or supplemented, and that is not excluded from the initial recognition and measurement provisions of FIN 45 pursuant to paragraphs 6 or 7 of that Interpretation;**
- ii. A retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets;**
- iii. Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument, except that it is both indexed to the issuer's own stock and classified in stockholders' equity in the issuer's statement of financial position, and therefore excluded from the scope of FASB Statement of Financial Accounting Standards No. 133, Accounting for Derivative Instruments and Hedging Activities (June 1998), pursuant to paragraph 11(a) of that Statement, as may be modified or supplemented; or**
- iv. Any obligation, including a contingent obligation, arising out of a variable interest (as referenced in FASB Interpretation No. 46, Consolidation of Variable Interest Entities (January 2003), as may be modified or supplemented) in an unconsolidated entity that is held by, and material to, the issuer, where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with, the issuer.**

This information, for the requested periods, can be found in the Company's Notes to Financial Statements, which have been posted on Pink Sheets.

Part E Issuance History

Item XVII List of securities offerings and shares issued for services in the past two years

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer (1) within the two-year period ending on the last day of the issuer's most recent fiscal year and (2) since the last day of the issuer's most recent fiscal year. The list shall include all offerings of securities, whether private or public, and shall indicate:

- (i) The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);**
- (ii) Any jurisdictions where the offering was registered or qualified;**
- (iii) The number of shares offered;**
- (iv) The number of shares sold;**
- (v) The price at which the shares were offered, and the amount actually paid to the issuer;**
- (vi) The trading status of the shares; and**
- (vii) Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities**

Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

The list shall also include all shares or any other securities or options to acquire such securities issued for services in the past two fiscal years and any interim periods, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities.

With respect to private offerings of securities, the list shall also indicate the identity of the persons who purchased securities in such private offering; provided, however, that in the event that any such person is an entity, the list shall also indicate (a) the identity of each natural person beneficially owning, directly or indirectly, more than five percent (5%) of any class of equity securities of such entity and (b) to the extent not otherwise disclosed, the identity of each natural person who controlled or directed, directly or indirectly, the purchase of such securities for such entity.

Date	Name of Person or Entity	Nature of each Offering or Service	Jurisdiction	Number of shares offered	Number of shares sold	Price shares were offered	Amount paid to the issuer	Value of Services to issuer	Trading status of the shares	Legend
1/6/2010	Big Apple Equities	504	NY		9,523,810	0.0021	\$20,000		Free Trading	None
1/11/2010	Big Apple Equities	504	NY	9,523,810					ESCROW	None
1/13/2010	Big Apple Equities	504	NY		9,523,810	0.0021	\$20,000		Free Trading	None
1/15/2010	Big Apple Equities	504	NY	9,523,810					ESCROW	None
1/19/2010	Big Apple Equities	504	NY		11,904,761	0.0021	\$25,000		Free Trading	None
1/22/2010	Big Apple Equities	504	NY	11,904,761					ESCROW	None
1/27/2010	Big Apple Equities	504	NY	8,680,556	8,680,556				Free Trading	None
2/2/2010	Big Apple Equities	504	NY	9,259,259	9,259,259	0.0027	\$25,000		Free Trading	None
2/10/2010	Big Apple Equities	504	NY		10,416,667	0.0024	\$25,000		Free Trading	None
2/16/2010	Big Apple Equities	504	NY	20,000,000					ESCROW	None
2/24/2010	Big Apple Equities	504	NY	17,857,142					ESCROW	None
2/22/2010	Big Apple Equities	504	NY		17,857,142	0.0014	\$25,000		Free Trading	None
2/22/2010	Big Apple Equities	504	NY		6,944,444	0.0018	\$12,500		Free Trading	None
3/8/2010	Big Apple Equities	504	NY	19,841,269					ESCROW	None
3/9/2010	Big Apple Equities	504	NY	6,944,444					ESCROW	None
3/3/2010	Big Apple Equities	504	NY		19,841,269	0.00126	\$25,000		Free Trading	None
3/16/2010	Big Apple Equities	504	NY		21,929,824	0.00114	\$25,000		Free Trading	None
3/18/2010	Big Apple Equities	504	NY	21,929,824					ESCROW	None
3/24/2010	Big Apple Equities	504	NY	25,000,000	25,000,000	0.001	\$25,000		Free Trading	None
3/24/2010	Big Apple Equities	504	NY		20,833,334	0.0012	\$25,000		Free Trading	None
3/30/2010	Big Apple Equities	504	NY		32,051,282	0.00078	\$25,000		Free Trading	None
3/31/2010	Big Apple Equities	504	NY	50,000,000					ESCROW	None

Connectyx Technologies Holdings Group, Inc.

4/5/2010	Big Apple Equities	504	NY	23,199,292					ESCROW	None
4/9/2010	Big Apple Equities	504	NY		41,666,666	0.0006	\$25,000		Free Trading	None
4/14/2010	Big Apple Equities	504	NY		41,666,666	0.0006	\$25,000		Free Trading	None
4/19/2010	Big Apple Equities	504	NY	34,000,000					ESCROW	None
4/22/2010	Big Apple Equities	504	NY		35,714,285	0.0007	\$25,000		Free Trading	None
4/26/2010	Big Apple Equities	504	NY	50,000,000					Free Trading	None
4/30/2010	Big Apple Equities	504	NY	16,000,000					Free Trading	None
4/28/2010	Big Apple Equities	504	NY		35,714,285	0.0007	\$25,000		Free Trading	None
5/6/2010	Big Apple Equities	504	NY	35,714,285					Free Trading	None
4/15/2010	Big Apple Equities	504	NY		4,000,000	0.01		\$40,000	Free Trading	None
5/15/2010	Big Apple Equities	504	NY		4,000,000	0.01		\$40,000	Free Trading	None
5/18/2010	Big Apple Equities	504	NY		41,666,667	0.0006	\$25,000		Free Trading	None
5/18/2010	Big Apple Equities	504	NY	25,000,000					ESCROW	None
6/3/2010	Big Apple Equities	504	NY		46,296,296	0.00054	\$25,000		Free Trading	None
6/15/2010	Big Apple Equities	504	NY		4,000,000	0.01		\$40,000	Free Trading	None
6/17/2010	Big Apple Equities	504	NY		52,083,333	0.00048	\$25,000		Free Trading	None
6/23/2010	Big Apple Equities	Note Conversion	NY	30,000,000	30,000,000	.0001			ESCROW	None
7/6/2010	Big Apple Equities	Note Conversion	FL	4,000,000	4,000,000	.0001			Free Trading	None
7/23/2010	Greenlife	Note Conversion	FL	80,000,000	80,000,000	.0001			Free Trading	None
8/02/2010	Greenlife	Note Conversion	FL	80,000,000	80,000,000	.0001			Free Trading	None
8/06/2010	Greenlife	Note Conversion	FL	70,579,833	70,579,833	.0001			Free Trading	None
*8/23/2010	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*11/09/2010	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*12/10/2010	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*01/12/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*01/27/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*03/17/2010	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*04/22/2010	Greenlife	Note Conversion	FL	3,000,000	3,000,000	.0005			Free Trading	None
*05/10/2011	Greenlife	Note Conversion	FL	3,000,000	3,000,000	.0005			Free Trading	None
*06/02/2011	Greenlife	Note Conversion	FL	4,000,000	4,000,000	.0005			Free Trading	None
*07/07/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*08/23/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*10/03/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None

*10/10/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*12/02/2011	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*01/13/2012	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*01/20/2012	Moro	Note Conversion	FL	4,000,000	4,000,000	.0005			Free Trading	None
*02/03/2012	Poulsheck	Note Conversion	FL	4,000,000	4,000,000	.0005			Free Trading	None
*02/13/2012	Greenlife	Note Conversion	FL	2,000,000	2,000,000	.0005			Free Trading	None
*03/01/2011	DeVought	Note Conversion	FL	4,000,000	4,000,000	.0005			Free Trading	None

*Post reverse stock split at a ratio of one (1) share for each fifty (50) shares

Part F Exhibits

The following exhibits must be either described in or attached to the disclosure statement:

Item XVIII Material Contracts

- A. Every material contract, not made in the ordinary course of business, that will be performed after the disclosure statement is posted through the OTC Disclosure and News Service or was entered into not more than two years before such posting. Also include the following contracts:**
- 1. Any contract to which directors, officers, promoters, voting trustees, security holders named in the disclosure statement, or the Designated Advisor for Disclosure are parties other than contracts involving only the purchase or sale of current assets having a determinable market price, at such market price;**
 - 2. Any contract upon which the issuer's business is substantially dependent, including but not limited to contracts with principal customers, principal suppliers, and franchise agreements;**
 - 3. Any contract for the purchase or sale of any property, plant or equipment for consideration exceeding 15 percent of such assets of the issuer; or**
 - 4. Any material lease under which a part of the property described in the disclosure statement is held by the issuer.**
- B. Any management contract or any compensatory plan, contract or arrangement, including but not limited to plans relating to options, warrants or rights, pension, retirement or deferred compensation or bonus, incentive or profit sharing (or if not set forth in any formal document, a written description thereof) in which any director or any executive officer of the issuer participates shall be deemed material and shall be included; and any other management contract or any other compensatory plan, contract, or arrangement in which any other executive officer of the issuer participates shall be filed unless immaterial in amount or significance.**
- C. The following management contracts or compensatory plans need not be included:**
- 1. Ordinary purchase and sales agency agreements;**
 - 2. Agreements with managers of stores in a chain organization or similar organization;**

3. **Contracts providing for labor or salesmen’s bonuses or payments to a class of security holders, as such; and**
4. **Any compensatory plan that is available to employees, officers or directors generally and provides for the same method of allocation of benefits between management and non-management participants**

The Corporation does not have any material contracts as defined in Item XVIII A, B or C.

Item XIX Articles of Incorporation and Bylaws

- A. A complete copy of the issuer’s articles of incorporation or in the event that the issuer is not a corporation, the issuer’s certificate of organization. Whenever amendments to the articles of incorporation or certificate of organization are filed, a complete copy of the articles of incorporation or certificate of organization as amended shall be filed.**

The Corporation has posted its Amended and Restated Articles of Incorporation on PinkSheets.com as of 9/30/10.

- (i) Amended and Restated Articles of Incorporation were filed with the state of Florida on 4-9-2010.

- B. A complete copy of the issuer’s bylaws. Whenever amendments to the bylaws are filed, a complete copy of the bylaws as amended shall be filed.**

The Corporation has posted its Bylaws on PinkSheets.com as of 12-31-2010.

- (i) Bylaws of Connectyx Technologies Holdings Group, Inc.

Item XX Purchases of Equity Securities by the Issuer and Affiliated Purchasers

- A. In the following tabular format, provide the information specified in paragraph (B) of this Item XX with respect to any purchase made by or on behalf of the issuer or any "Affiliated Purchaser" (as defined in paragraph (C) of this Item XX) of shares or other units of any class of the issuer's equity securities.**

ISSUER PURCHASES OF EQUITY SECURITIES				
Period	Column (a) Total Number of Shares (or Units) Purchased	Column (b) Average Price Paid per Share (or Unit)	Column (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Column (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
Month #1 (identify beginning and ending dates)	N/A	N/A	N/A	N/A

Month #2 (identify beginning and ending dates)	N/A	N/A	N/A	N/A
Month #3 (identify beginning and ending dates)	N/A	N/A	N/A	N/A
Total	N/A	N/A	N/A	N/A

B. The table shall include the following information for each class or series of securities for each month included in the period covered by the report:

1. **The total number of shares (or units) purchased (Column (a)). Include in this column all issuer repurchases, including those made pursuant to publicly announced plans or programs and those not made pursuant to publicly announced plans or programs. Briefly disclose, by footnote to the table, the number of shares purchased other than through a publicly announced plan or program and the nature of the transaction (e.g., whether the purchases were made in open-market transactions, tender offers, in satisfaction of the company's obligations upon exercise of outstanding put options issued by the company, or other transactions).**
2. **The average price paid per share (or unit) (Column (b)).**
3. **The total number of shares (or units) purchased as part of publicly announced repurchase plans or programs (Column (c)).**
4. **The maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs (Column (d)).**

Instructions to paragraphs (B)(3) and (B)(4) of this Item XX:

- a. **In the table, disclose this information in the aggregate for all plans or programs publicly announced.**
- b. **By footnote to the table, indicate:**
 - i. **The date each plan or program was announced;**
 - ii. **The dollar amount (or share or unit amount) approved;**
 - iii. **The expiration date (if any) of each plan or program; iv. Each plan or program that has expired during the period covered by the table; and**
 - iv. **Each plan or program the issuer has determined to terminate prior to expiration, or under which the issuer does not intend to make further purchases.**

C. For purposes of this Item XX, "Affiliated Purchaser" means:

- 1. A person acting, directly or indirectly, in concert with the issuer for the purpose of acquiring the issuer's securities; or**
- 2. An affiliate who, directly or indirectly, controls the issuer's purchases of such securities, whose purchases are controlled by the issuer, or whose purchases are under common control with those of the issuer; provided, however, that "Affiliated Purchaser" shall not include a broker, dealer, or other person solely by reason of such broker, dealer, or other person effecting purchases on behalf of the issuer or for its account, and shall not include an officer or director of the issuer solely by reason of that officer or director's participation in the decision to authorize purchases by or on behalf of the issuer.**

Item XXI Issuer's Certifications

I, Ronn Schuman, certify that:

I have reviewed this Initial Information and Disclosure Statement of Connectyx Technologies Holdings Group, Inc.;

- 1. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and not misleading with respect to the period covered by this disclosure statement; and**
- 2. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.**



Signature: _____

Date: May 15, 2012

Name: Ronn Schuman

Title: Connectyx Technologies Holdings Group, Inc., President, CEO and Director

CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC.

FINANCIAL REPORT
&
NOTES TO THE FINANCIAL STATEMENTS
FOR THE QUARTER ENDED March 31, 2012

CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC.

NOTES TO FINANCIAL STATEMENTS

March 31, 2012

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

NATURE OF BUSINESS: The Company provides products in the health care market which includes business intelligent software, which provides revenue cycle and remittance processing, data warehousing and knowledge management in a user friendly environment.

BASIS OF ACCOUNTING: These financial statements have been prepared under the accrual method of accounting.

REVENUE RECOGNITION: The Company recognizes revenues under the accrual method of accounting. When materials are delivered and accepted by customers, invoices are generated and revenues are recognized.

INCOME TAXES: There has been no provision for income tax expense since the Company is currently operating at a loss and has no income tax liability.

PROPERTY AND EQUIPMENT: Property and equipment are stated at cost. Depreciation is computed using the straight -line method over five years. Intangible assets are amortized over 5 to 15 years. Depreciation and amortization expense for the quarter ended March 31, 2012 totaled \$3,864 and is included in operating expenses.

Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to income as incurred. Upon sale or retirement of items of property and equipment, the cost and related accumulated depreciation are eliminated from the accounts and the resulting gain and loss, if any, is reflected in earnings of the period of disposition

LONG-LIVED ASSETS: Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset and long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. There were no such impairments recorded during the quarter.

ESTIMATES: The preparation of financial statements in conformity with generally accepted accounting principles requires the Company's management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results may differ from those estimates.

FAIR VALUE OF FINANCIAL INSTRUMENTS: The carrying amount of the Company's notes payable approximates their fair value.

ADVERTISING COSTS: The Company incurred advertising costs of \$217 during the first quarter of 2012. The Company's policy is to expense advertising costs as incurred. Advertising costs are included in operating expenses.

CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC.
NOTES TO FINANCIAL STATEMENTS
March 31, 2012

NOTE B – CASH:

Cash consists entirely of demand deposits with banking institutions. At March 31, 2012, the Company did not have any funds in excess of the \$250,000 federally insured limit.

NOTE C – ACCOUNTS RECEIVABLE:

Net accounts receivable consisted of the following at March 31, 2012:

Commercial customers \$ 115,411

Accounts receivable are recorded when invoices are issued. The Company evaluates the collectability of its receivables based on a combination of factors. In circumstances where it is aware of a specific customer's inability to meet its financial obligations, it records a specific reserve to reduce the amounts recorded to what it believes will be collected. For all other customers, it recognizes reserves for bad debt based on historical experience of bad debts as a percent of revenues, adjusted for relative improvements or deteriorations in the agings and changes in current economic conditions. The allowance for uncollectible receivables at March 31, 2012 was \$9000.

NOTE D – LONG TERM NOTES PAYABLE:

The long term notes payable at March 31, 2012 consisted of the following:

An unsecured note payable to an individual with an annual interest rate of 12%.	\$ 30,048
An unsecured note payable to an individual with an annual interest rate of 12%.	12,500
An unsecured note payable to an individual with an annual interest rate of 15%.	39,600
An unsecured note payable to an individual with an annual interest rate of 10%.	5,000
An unsecured note payable to an individual with an annual interest rate of 10%.	87,942
An unsecured note payable to an individual with an annual interest rate of 8%.	29,260

TOTAL LONG TERM NOTES PAYABLE \$204,349

\$175,089 notes payable have a convertible feature. They can be converted into common shares from .005 to .0005 per share.

CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC.
NOTES TO FINANCIAL STATEMENTS
March 31, 2012

NOTE E – LEASES:

The company leases certain office equipment and software. These leases are classified as operating leases. The future minimum lease payments under the leases are as follows as of March 31, 2011:

2012	7,830
2013	1,104
Total minimum lease payments	\$ 8,934

NOTE F - INVENTORY:

Inventory is reported at cost. The inventory consists of goods held for sale to customers.

NOTE G – EQUITY

There are three classes of shares authorized.

Common stock has 1,100,000,000 shares authorized and 170,052,477 shares outstanding.

Preferred stock series A has 200,000,000 shares authorized and 34,109,750 shares outstanding. Preferred Series A has 10 votes per share and is convertible to 35% of equity.

Preferred stock series B has 5,000,000 shares authorized and 256,000 shares outstanding. Preferred Series B is convertible to common stock with a 20% discount of the average closing bid price for the 10 consecutive trading days immediately prior to the date of notice of conversion. Each share also includes a warrant with the exercise price of \$.05.

8,636,424 warrants are outstanding. The exercise price ranges from .05 to .50 per warrant.

A reverse stock split was executed on August 23, 2010 at 50:1.

Connectyx Technologies Corp
Unaudited Profit and Loss
for the quarter ended March 31

	1/1 - 3/31/12
Sales	\$ 24,693
Cost of Goods Sold	<u>4,779</u>
Gross Profit	<u>19,914</u>
Expenses	
Advertising	217
Amortization	1,251
Depreciation	2,613
Bad Debt Expense	53
Bank Service Charges	499
Cash Discounts	-
Commission	900
Payroll Expenses	31,478
Insurance	7,587
Interest Expense	4,049
Marketing and PR	1,811
Office Expense	8,072
Professional Fees	37,231
Occupancy	4,107
Travel and meals	<u>5,050</u>
Total Expenses	<u>104,918</u>
Gain on Sale of Fixed Assets	
Cancellation of debt	
Net Income (Loss)	<u><u>\$ (85,004)</u></u>

Connectyx Technologies Corp
Unaudited Balance Sheet
As of March 31 , 2012

Assets

	3/31/2012
Cash	\$ 12,283
Accounts Receivable, net	106,411
Inventory	7,583
Fixed Assets, net	15,408
Intangible Assets, net	<u>74,580</u>
Total Assets	<u><u>216,265</u></u>

Liabilities & Equity

Liabilities

Accounts Payable	148,958
Accrued Interest	27,461
Deferred Expenses	371,668
Notes Payable short term	-
Notes Payable long term	<u>204,350</u>

Total Liabilities 752,437

Equity

Additional Paid in Capital	1,803,967
Capital Stock	1,131,002
Preferred Series A	34,110
Preferred Series B	256,000
Treasury Stock	(9,900)
Retained Earnings	<u>(3,751,351)</u>

Total Equity (536,172)

Total Liabilities & Equity \$ 216,265

Connectyx Technologies Corp
Unaudited Statement of Cash Flows
for the quarter ended March 31, 2012

Operating Activities	
Net Income (Loss)	\$ (85,004)
Adjustments to reconcile net income to net cash provided by operating activities:	
Depreciation and Amortization	3,864
Accounts Receivable	360
Bad Debt Reserve	-
Accounts Payable	2,440
Accrued Interest	1,262
Deferred Expenses	43,750
Repayment of short term Debt	(14,194)
Proceeds from Short Term Debt	-
Inventory	-
	<hr/>
Net cash used by operating activities	<u>(47,522)</u>
Investing Activities	
Purchase of assets	(3,189)
Financing Activities	
Payments of Long Term Debt	(77,146)
Proceeds from Debt	-
Proceeds from issuance of stock	<u>128,500</u>
Net cash provided by financing activities	<u>51,354</u>
Net cash increase for period	643
Cash at beginning of period	<u>11,640</u>
Cash at end of period	<u><u>\$ 12,283</u></u>

Connectyx
 Unaudited
 Statement of Shareholder's Equity

	Common Stock	Preferred Stock Series A	Preferred Stock Series B	Common Stock		Preferred Stock Series A	Preferred Stock Series B	Retained Earnings	Treasury Stock	Total
	Units	Units	Units	Amount	APIC					
Beg Jan 1 2012	115,114,810	34,109,750	234,000	\$ 1,125,590	\$ 1,702,879	\$ 34,110	\$ 234,000	\$ (3,666,347)	\$ (9,900)	\$ (579,668)
Net Income								(85,004)		(85,004)
Common Stock Issued	54,937,667			5,412	101,088					106,500
Common Stock retired										-
Preferred Stock Issued			22,000				22,000			22,000
Balance Mar 31, 2012	<u>170,052,477</u>	<u>34,109,750</u>	<u>256,000</u>	<u>\$ 1,131,002</u>	<u>\$ 1,803,967</u>	<u>\$ 34,110</u>	<u>\$ 256,000</u>	<u>\$ (3,751,351)</u>	<u>\$ (9,900)</u>	<u>\$ (536,172)</u>